http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2023, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 20 Nov 2023 08:48:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++BIOCEPT+INC++++++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/22435223.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++BIOCEPT+INC++++++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/22435223.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++BIOCEPT+INC++++++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/22435223.html Mon, 20 Nov 2023 08:48:00 -0500 BIOC O.00024391 http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++BIOCEPT+INC++++++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/22435223.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++BIOCEPT+INC++++++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/22435223.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++25-NSE+++++BIOCEPT+INC++++++++++++++++++++++++++++Filed+by%3A+Nasdaq+Stock+Market+LLC/22435223.html Mon, 20 Nov 2023 08:48:00 -0500 BIOC O.00024391 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+16/22293992.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+16/22293992.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+16/22293992.html Fri, 20 Oct 2023 06:06:00 -0500 BIOC O.00024391 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+16/22293992.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+16/22293992.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+16/22293992.html Fri, 20 Oct 2023 06:06:00 -0500 BIOC O.00024391 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+13/22275058.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+13/22275058.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+13/22275058.html Mon, 16 Oct 2023 08:54:00 -0500 BIOC O.00024391 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+13/22275058.html Visit StreetInsider.com at http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+13/22275058.html for the full story. http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BIOCEPT+INC+++++++++++++++For%3A+Oct+13/22275058.html Mon, 16 Oct 2023 08:54:00 -0500 BIOC O.00024391 http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Press+Releases/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Visit StreetInsider.com at http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html for the full story. http://www.streetinsider.com/Business+Wire/Enrollment+Completed+in+the+Feasibility+Phase+of+the+FORESEE+Clinical+Trial+with+Biocept%E2%80%99s+CNSide%E2%84%A2+Assay+to+Evaluate+Patients+with+Leptomeningeal+Metastases/22184513.html Thu, 21 Sep 2023 08:00:00 -0500 A.36059387 BIOC O.00024391 O.35359770 http://www.streetinsider.com/Corporate+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html for the full story. http://www.streetinsider.com/Corporate+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Fri, 08 Sep 2023 08:01:04 -0500 BIOC PSTV http://www.streetinsider.com/Corporate+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html for the full story. http://www.streetinsider.com/Corporate+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Fri, 08 Sep 2023 08:01:04 -0500 BIOC PSTV http://www.streetinsider.com/FDA/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Visit StreetInsider.com at http://www.streetinsider.com/FDA/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html for the full story. http://www.streetinsider.com/FDA/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Fri, 08 Sep 2023 08:01:04 -0500 BIOC PSTV http://www.streetinsider.com/FDA/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Visit StreetInsider.com at http://www.streetinsider.com/FDA/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html for the full story. http://www.streetinsider.com/FDA/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Fri, 08 Sep 2023 08:01:04 -0500 BIOC PSTV http://www.streetinsider.com/Hot+Corp.+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Visit StreetInsider.com at http://www.streetinsider.com/Hot+Corp.+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html for the full story. http://www.streetinsider.com/Hot+Corp.+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Fri, 08 Sep 2023 08:01:04 -0500 BIOC PSTV http://www.streetinsider.com/Hot+Corp.+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Visit StreetInsider.com at http://www.streetinsider.com/Hot+Corp.+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html for the full story. http://www.streetinsider.com/Hot+Corp.+News/Biocept+%28BIOC%29+Signs+CNSide+Licensing+Agreement+with+Plus+Therapeutics+%28PSTV%29/22141351.html Fri, 08 Sep 2023 08:01:04 -0500 BIOC PSTV http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html for the full story. http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Fri, 08 Sep 2023 08:00:00 -0500 A.06822034 BIOC O.00024391 O.00066617 O.20026344 PSTV http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html for the full story. http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Fri, 08 Sep 2023 08:00:00 -0500 A.06822034 BIOC O.00024391 O.00066617 O.20026344 PSTV http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html for the full story. http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Fri, 08 Sep 2023 08:00:00 -0500 A.06822034 BIOC O.00024391 O.00066617 O.20026344 PSTV http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html for the full story. http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Fri, 08 Sep 2023 08:00:00 -0500 A.06822034 BIOC O.00024391 O.00066617 O.20026344 PSTV http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html for the full story. http://www.streetinsider.com/Press+Releases/Biocept+Signs+CNSide%E2%84%A2+Licensing+Agreement+with+Plus+Therapeutics/22141317.html Fri, 08 Sep 2023 08:00:00 -0500 A.06822034 BIOC O.00024391 O.00066617 O.20026344 PSTV